Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing
Open accessThe DOI matches its Crossref record; 56 of the 57 references it cites were found in a registry or an index.
Abstract
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery. Nevertheless, key limitations of the current drug connectivity-mapping paradigm have been long overlooked, including the lack of effective means to determine optimal query gene signatures. Results: The novel approach Dr Insight implements a frame-breaking statistical model for the ‘hand-shake’ between disease and drug data. The genome-wide screening of concordantly expressed genes (CEGs) eliminates the need for subjective selection of query signatures, added to eliciting better proxy for potential disease-specific drug targets. Extensive comparisons on simulated and real cancer datasets have validated the superior performance of Dr Insight over several popular drug-repurposing methods to detect known cancer drugs and drug–target interactions. A proof-of-concept trial using the TCGA breast cancer dataset demonstrates the application of Dr Insight for a comprehensive analysis, from redirection of drug therapies, to a systematic construction of disease-specific drug-target networks. Availability and implementation: Dr Insight R package is available at https://cran.r-project.org/web/packages/DrInsight/index.html. Supplementary information: Supplementary data are available at Bioinformatics online.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASGARD on each cluster is related to DrInsight, a concordantly expressed genes (CEG) based, enhanced drug repurposing method compared to other signature-based searching methods30.”
From ASGARD is a single-cell guided pipeline to aid repurposing of drugs (2023) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206 · cited 1×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the…”
MethodKEGG: Kyoto Encyclopedia of Genes and Genomes
Kanehisa, M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.27 · Cited by 37,077
KEGG: Kyoto Encyclopedia of Genes and Genomes
Ogata, H., Goto, S., Sato, K., Fujibuchi, W., Bono, H., & Kanehisa, M. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.1.29 · Cited by 31,232 · cited 2×
“Finally, in combination with several external gene set databases such as Gene Ontology (GO) (Ashburner et al., 2000), Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000) and NCI Pathway Interaction Database (PID) (Schaefer et al., 2009), the drug–CEG interactions serve as the skeleton to assemble…”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
Self-citation
Cited by
Low, Z. Y., Farouk, I. A., & Lal, S. K. (2020) · Viruses · doi:10.3390/v12091058 · Cited by 180
“0001 and an absolute fold change of ≥4 [20].”
BackgroundYang, C. G., Zhang, H., Chen, M., Wang, S., Qian, R., Zhang, L., Huang, X., Wang, J., Liu, Z., Qin, W., et al. (2022) · eLife · doi:10.7554/elife.71880 · Cited by 180
“By contrast, relatively limited efforts have been made to standardize the generation of query signatures ( Chan et al., 2019 ; Wen et al., 2016 ; Wen et al., 2015 ).”
Drug repurposing for COVID-19: Approaches, challenges and promising candidates
Ng, Y. L., Salim, C. K., & Chu, J. J. H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107930 · Cited by 159
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes
DeMeo, B., Nesbitt, C., Miller, S. A., Burkhardt, D. B., Lipchina, I., Fu, D., Holderrieth, P., Kim, D., Kolchenko, S., Szałata, A., et al. (2025) · Science · doi:10.1126/science.adi8577 · Cited by 87
“The comparison models included two classical baseline methods: a k - nearest Hits Non-hits”
ASGARD is a single-cell guided pipeline to aid repurposing of drugs
He, B., Xiao, Y., Liang, H., Huang, Q., Du, Y., Li, Y., Garmire, D., Sun, D., & Garmire, L. X. (2023) · Nature Communications · doi:10.1038/s41467-023-36637-3 · Cited by 57
On the Role of Artificial Intelligence in Genomics to Enhance Precision Medicine
Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Cernea, A., de la Viña, J. F. S., & Fernández‐Martínez, J. L. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s205082 · Cited by 60
Considerations and challenges for sex-aware drug repurposing
Fisher, J. L., Jones, E. F., Flanary, V. L., Williams, A. S., Wilk, E. J., & Lasseigne, B. N. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00420-8 · Cited by 54
“Insight (189) - signatureSearch (111) - Sanseau P et al.”
BackgroundPrediction of repurposed drugs for treating lung injury in COVID-19
He, B., & Garmire, L. (2020) · F1000Research · doi:10.12688/f1000research.23996.2 · Cited by 33
Khatami, S. G., Mubeen, S., Bharadhwaj, V. S., Kodamullil, A. T., Hofmann‐Apitius, M., & Domingo‐Fernándéz, D. (2021) · npj Systems Biology and Applications · doi:10.1038/s41540-021-00199-1 · Cited by 28
deAndrés‐Galiana, E. J., Bea, G., Fernández‐Martínez, J. L., & Saligan, L. N. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2019.103492 · Cited by 24
Scoring functions for drug-effect similarity
Struckmann, S., Ernst, M., Fischer, S., Mah, N., Fuellen, G., & Möller, S. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa072 · Cited by 25
“Most likely, also other parameters of a complex method such as Dr Insight could be evaluated and potentially be improved, based on a systematic evaluation in a setup as demonstrated in the current study.”
MethodKoudijs, K. K. M., van Scheltinga, A. G. T. T., Böhringer, S., Schimmel, K. J. M., & Guchelaar, H. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000370 · Cited by 22
Identification of HOX signatures contributing to oral cancer phenotype
Padam, K. S. R., Morgan, R., Hunter, K. D., Chakrabarty, S., Kumar, N. A. N., & Radhakrishnan, R. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-14412-6 · Cited by 20
Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors
Singha, M., Pu, L., Stanfield, B. A., Uche, I. K., Rider, P. J. F., Kousoulas, K. G., Ramanujam, J., & Bryliński, M. (2022) · BMC Cancer · doi:10.1186/s12885-022-10293-0 · Cited by 19
“To address this issue, Dr. Insight implements a new statistical model utilizing the genome-wide screening of concordantly expressed genes (CEGs) [38].”
MethodDai, D., Liu, L., Guo, Y., Shui, Y., & Wei, Q. (2022) · Cancers · doi:10.3390/cancers15010057 · Cited by 17
“CMap analysis was conducted by R package “DrInsight” [22].”
MethodRobust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
Fernández‐Martínez, J. L., Álvarez-Machancoses, Ó., deAndrés‐Galiana, E. J., Bea, G., & Kloczkowski, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103594 · Cited by 18
“A more detailed drug repositioning was performed via Dr Insights (Chan et al., 2019) that uses the Connectivity Map (CMAP) transcriptomic experiments in different types of cell lines [35,36].”
BackgroundMethodInfluentialSalame, N., Fooks, K., El-Hachem, N., Bikorimana, J., Mercier, F., & Rafei, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852143 · Cited by 18
“In the past decade, substantial technical advances in high throughput molecular technologies, at the DNA, RNA and protein levels illuminated on the complexity of human biology and created unprecedented levels of datasets (Chen and Butte, 2016).”
BackgroundInformatics on Drug Repurposing for Breast Cancer
Zhou, H., Liu, H., Yu, Y., Yuan, X. F., & Xiao, L. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s417563 · Cited by 15
“In order to solve this issue, Chan et al developed Dr Insight (Drug Repurposing: Integration and Systematic Investigation of Genomic High-Throughput data), which employed order statistics to directly measure the reverse association between disease and drug-perturbed expression data genome-wide.(14) This automated tool…”
MethodDrug mechanism enrichment analysis improves prioritization of therapeutics for repurposing
Garana, B. B., Joly, J. H., Delfarah, A., Hong, H., & Graham, N. A. (2023) · BMC Bioinformatics · doi:10.1186/s12859-023-05343-8 · Cited by 12
Dai, D., Guo, Y., Shui, Y., Li, J., Jiang, B., & Wei, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.775562 · Cited by 11
“In the current study, the “DrInsight” R package was used to perform the CMap analysis, which aimed to find potential drugs targeted for the RR and PD-L1-high group (Chan et al., 2019).”
MethodLiu, C., Zhang, Y., Liang, Y., Zhang, T., & Wang, G. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae490 · Cited by 10
“To highlight these advantages, we implemented DrInsight [30] and iLINCS [22] on three TCGA datasets(TCGA-SKCM,TCGA-LUAD,TCGA-KIRC),comparingtheir predictive capabilities with those of DrugReSC using the same groundlists(Methods).”
MethodDrug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens
Falvo, P., Orecchioni, S., Roma, S., Raveane, A., & Bertolini, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200817104912 · Cited by 10
deAndrés‐Galiana, E. J., Fernández‐Martínez, J. L., Álvarez-Machancoses, Ó., Bea, G., Galmarini, C. M., & Kloczkowski, A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.106029 · Cited by 7
“From this perspective, given a set of altered genes, drugs in CMAP library are score-based on a disease-drug connectivity and rank-based on the two-sample Kolmogorov-Smirnov test to determine which ones are more likely to have either a positive effect or an amplified negative effect [31].”
MethodStrategies for the treatment of breast cancer: from classical drugs to mathematical models
Costa, A., & Vale, N. (2021) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2021316 · Cited by 7
Fong, L. W. R., Lee, J., Lin, H., Ueno, N. T., & Zhang, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-06451-w · Cited by 5
Chen, R., Wang, X., Deng, X., Chen, L., Liu, Z., & Li, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.904909 · Cited by 5
“DrInsight can automatically create cancer signatures from a whole ranked gene list of differential analysis, avoiding the subjective impact during the cancer signature identi fi cation.”
MethodSelf-citationLiao, J., Yi, H., Wang, H., Yang, S., Jiang, D., Huang, X., Zhang, M., Shen, J., Lu, H., & Niu, Y. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae659 · Cited by 4
Dai, D., Wu, D., Ni, R., Li, P., Tian, Z., Shui, Y., Hu, H., & Wei, Q. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1162409 · Cited by 4
“, 2017) from the R package “DrInsight” (Chan et al., 2019).”
BackgroundPrediction of repurposed drugs for treating lung injury in COVID-19Preprint
He, B., & Garmire, L. X. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2003.14333 · Cited by 4
“DrInsight Package 17 (version: 0.1.1) was used for this purpose, and the outlier-sum (OS) statistic was retrieved, which models the overall disease-drug connectivity by aggregating disease transcriptome changes with drug perturbation.”
InfluentialApplications of Computational Biology in Gastrointestinal Malignancies
Gupta, M. K., & Vadde, R. (2020) · Diagnostics and therapeutic advances in GI malignancies · doi:10.1007/978-981-15-6487-1_13 · Cited by 3
The Diagnostic and Prognostic Values of HOXA Gene Family in Kidney Clear Cell Renal Cell Carcinoma
Zong, X., Fu, J., Wang, Z., & Wang, Q. (2022) · Journal of Oncology · doi:10.1155/2022/1762637 · Cited by 3
“Insight [28] provides a novel systematic connectivity mapping method to connect drugs in the CMAP data set with query data.”
MethodGene Signature-Based Drug Repositioning
Jia, Z., Song, X., Shi, J., Wang, W., & He, K. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.101377 · Cited by 4
STADS: Spatial Transcriptomics to Aid Drug-reposition Recommendation
Karaaslanli, A., Guo, Y., Liang, H., Huang, Z. N., & Garmire, L. X. (2023) · IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · doi:10.1109/bibm58861.2023.10385738 · Cited by 1
“Among the different drug repurposing approaches, omics-based drug repurposing, particularly those based on transcriptomics, has shown success [1].”
BackgroundCOMPUTATIONAL DRUG REPURPOSING FOR BREAST CANCER SUBTYPES
Dhara, R. (2019) · Scholarship at UWindsor (University of Windsor) · Cited by 1
Network-based Computational Drug Repurposing and Repositioning for Breast Cancer Disease
Ulaganathan, P. (2020) · Scholarship at UWindsor (University of Windsor) · Cited by 1
Peyvandipour, A. (2020) · Human Biology
Considerations and Challenges for Sex-Aware Drug RepurposingPreprint
Fisher, J., Jones, E., Flanary, V. L., Williams, A. S., Ramsey, E., & Lasseigne, B. N. (2021) · Preprints.org · doi:10.20944/preprints202112.0380.v1
Considerations and Challenges for Sex-Aware Drug RepurposingPreprint
Fisher, J., Jones, E., Flanary, V. L., Williams, A. A., Ramsey, E., & Lasseigne, B. N. (2022) · Preprints.org · doi:10.20944/preprints202112.0380.v2
Zhang, J., Zhou, Q., Zheng, Y., You, X., Jin, L., Chen, C., & Pan, M. (2022) · Research Square · doi:10.21203/rs.3.rs-2226299/v1
Ляшенко, И. С., Romanova, M. V., Гончарова, А. С., Владиславовна, Х. Д., Galina, A. V., Гурова, С. В., Filippova, S. Y., & Shatova, Y. S. (2024) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2024-5-1-3
Chou, A., Gilliland, M., Reall, M., Frank, E., Jackson, M., Keele, J., & Pickett, B. E. (2025) · Journal of Visualized Experiments · doi:10.3791/68732
Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy
Cheng, O., Tran, T. T., Chen, Y. A., & Tan, A. C. (2025) · Pharmaceuticals · doi:10.3390/ph18111769
Garana, B. B., Joly, J. H., Delfarah, A., Hong, H., & Graham, N. A. (2024) · Figshare · doi:10.6084/m9.figshare.26591531
STDrug enables spatially informed personalized drug repurposing from spatial transcriptomicsPreprint
Yang, Y., Unjitwattana, T., Zhou, S. W., Kadomoto, S., Yang, X., Chen, T., Karaaslanli, A., Du, Y., Zhang, W., Liang, H., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.03.715101
SIEVE: Locus-Anchored Drug Prioritization for Complex DisordersPreprint
Strobl, E. V. (2026) · medRxiv · doi:10.64898/2026.04.15.26350958
Ito, R., Hamano, M., Kawasaki, R., Watanabe, H., Matsuo, A., & Yamanishi, Y. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01991-y
Ren, Z., Ren, Y., Li, Z., Ge, S., Xu, Y., & Xu, H. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.01.756124
“Drug efficacy is then assessed using DrInsight (58), which identifies concordantly expressed genes against the L1000 dataset, computes connectivity via an outlier-sum approach, and evaluates significance with a Kolmogorov-Smirnov test (59) followed by Benjamini-Hochberg correction (60).”
Metadata
- Authors
- Chan, J., Wang, X., Turner, J. A., Baldwin, N. E., & Gu, J.
- Affiliations
- Baylor University (US)
- Baylor Scott & White Research Institute (US)
- Stephen F. Austin State University (US)
- Corresponding author
- Gu, Jinghua
- Venue
- Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-08
- Volume
- 35
- Issue
- 16
- Pages
- 2818-2826
- ISSN
- 1367-4803 (ISSN-L)
- 1367-4811
- PMC
- PMC6691331
- OpenAlex
- W2910665348
- Cited by
- 50
- References
- 57
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 12 · 2021: 7 · 2020: 13 · 2019: 3
- FWCI
- 5.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Bioinformatics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Index of Texas Archaeology Open Access Grey Literature from the Lone Star State (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (U19AI082715)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Keywords
- computational drug repurposing, drug-target interactions, cancer drug targets, breast cancer
- MeSH terms
- Software, Models, Statistical, Drug Discovery, Drug Repositioning, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.